The economic value of personalized medicine tests: What we know and what we need to know

Genetics in Medicine

Volumn 16, Issue 3, 2014, Pages 251-257

  Phillips, Kathryn A ^a,b   Ann Sakowski, Julie ^a   Trosman, Julia ^a,b   Douglas, Michael P ^a,c   Liang, Su Ying ^a,d   Neumann, Peter ^e  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UCSF Institute for Human Genetics Center for Business Models in Healthcare   (United States)

^c McKing Consulting Corporation   (United States)

^d PALO ALTO MEDICAL FOUNDATION RESEARCH INSTITUTE   (United States)

^e TUFTS MEDICAL CENTER   (United States)

Author keywords

Cost effectiveness; Economic value; Ethical legal social implications (ELSI); Genetic tests; Personalized medicine

Indexed keywords

ARTICLE; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; FOOD AND DRUG ADMINISTRATION; GENETIC ANALYSIS; HEALTH CARE COST; HEALTH ECONOMICS; HUMAN; MORTALITY; PERSONALIZED MEDICINE; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; REGISTER; COST BENEFIT ANALYSIS; ECONOMICS; GENETIC SCREENING; PROCEDURES; STATISTICS AND NUMERICAL DATA; UNITED STATES;

COST-BENEFIT ANALYSIS; GENETIC TESTING; HUMANS; INDIVIDUALIZED MEDICINE; QUALITY-ADJUSTED LIFE YEARS; REGISTRIES; UNITED STATES;

EID: 84895787381     PISSN: 10983600     EISSN: 15300366     Source Type: Journal    
DOI: 10.1038/gim.2013.122     Document Type: Article

References (39)

1. Armstrong K. Can genomics bend the cost curve? JAMA 2012;307:1031-1032
2. Clinically Relevant Genetic Variants Resource: A Unified Approach for Identifying Genetic Variants for Clinical Use (U01). http://grants.nih.gov/ grants/guide/rfafiles/ rfa-hg-12-016.html. Accessed 10 December, 2012
3. Cohen JT, Neumann PJ, Weinstein MC. Does preventive care save money? Health economics and the presidential candidates. N Engl J Med 2008;358:661-663
4. Phillips KA. Closing the evidence gap in the use of emerging testing technologies in clinical practice. JAMA 2008;300:2542-2544
5. Phillips KA, Liang SY, Van Bebber S; Canpers Research Group. Challenges to the translation of genomic information into clinical practice and health policy: Utilization, preferences and economic value. Curr Opin Mol Ther 2008;10:260-266
6. Neumann PJ, Greenberg D, Olchanski NV, Stone PW, Rosen AB. Growth and quality of the cost-utility literature, 1976-2001. Value Health 2005;8:3-9
7. Tufts Cost-Effectiveness Analysis Registry. www.cearegistry.org. Accessed 10 December 2012
8. GAPP Finder. Version 1.0. http://www.hugenavigator.net/GAPPKB/ topicStartPage.do. Accessed 2 May 2013
9. Food and Drug Administration Table of Pharmacogenomic Biomarkers in Drug Labels. http://www.fda.gov/drugs/scienceresearch/researchareas/ pharmacogenetics/ucm083378.htm. Accessed 2 May 2013
10. Khoury MJ, Bowen MS, Burke W, et al. Current priorities for public health practice in addressing the role of human genomics in improving population health. Am J Prev Med 2011;40:486-493
11. Centers for Disease Control and Prevention Genomic Tests by Levels of Evidence. http://www.cdc.gov/genomics/gtesting/tier.htm. Accessed 1 May 2013
12. Neumann PJ, Rosen AB, Greenberg D, et al. Can we better prioritize resources for cost-utility research? Med Decis Making 2005;25:429-436
13. Murphy S, Xu J, Kochanek K. Deaths: Preliminary data for 2010. National Center for Health Statistics: Hyattsville, MD, 2012
14. Agency for Healthcare Research and Quality. Total Expenses and Percent Distribution for Selected Conditions by Type of Service: United States, 2009. Medical Expenditure Panel Survey Household Component Data. Generated interactively. http://meps.ahrq.gov/mepsweb/data-stats/tables-compendia-hh- interactive.jsp?-SERVICE=MEPSSocket0&-PROGRAM=MEPSPGM.TC.SA S&File=HCFY2009&Table=HCFY2009-CNDXP-C&-Debug=. Accessed 2 May 2013
15. Beaulieu M, de Denus S, Lachaine J. Systematic review of pharmacoeconomic studies of pharmacogenomic tests. Pharmacogenomics 2010;11:1573-1590
16. Carlson JJ, Henrikson NB, Veenstra DL, Ramsey SD. Economic analyses of human genetics services: A systematic review. Genet Med 2005;7:519-523
17. Djalalov S, Musa Z, Mendelson M, Siminovitch K, Hoch J. A review of economic evaluations of genetic testing services and interventions (2004-2009). Genet Med 2011;13:89-94
18. Giacomini M, Miller F, O'Brien BJ. Economic considerations for health insurance coverage of emerging genetic tests. Community Genet 2003;6:61-73
19. Phillips KA, Van Bebber SL. A systematic review of cost-effectiveness analyses of pharmacogenomic interventions. Pharmacogenomics 2004;5:1139-1149
20. Vegter S, Boersma C, Rozenbaum M, Wilffert B, Navis G, Postma MJ. Pharmacoeconomic evaluations of pharmacogenetic and genomic screening programmes: A systematic review on content and adherence to guidelines. Pharmacoeconomics 2008;26:569-587
21. Wong WB, Carlson JJ, Thariani R, Veenstra DL. Cost effectiveness of pharmacogenomics: A critical and systematic review. Pharmacoeconomics 2010;28:1001-1013
22. Neumann PJ, Fang CH, Cohen JT. 30 years of pharmaceutical costutility analyses: Growth, diversity and methodological improvement. Pharmacoeconomics 2009;27:861-872
23. Gold M, Siegel J, Russel L, Weinstein M. Cost-Effectiveness in Health and Medicine. Oxford University Press: New York, NY, 1996
24. National Institutes of Health Common Fund Teleconference Executive Summary: Economics of Personalized Health Care and Prevention. http://commonfund. nih.gov/pdf/HealthEconomics-Personalized-Health-Care-summary- REV-9-28-12.pdf. Accessed 21 February 2013
25. Phillips KA, Sakowski JA, Liang SY, Ponce NA. Economic Perspectives on Personalized Health Care and Prevention. Forum for Health Economics and Policy 2013;16(2):57-86
26. Sculpher M. Subgroups and heterogeneity in cost-effectiveness analysis. Pharmacoeconomics 2008;26:799-806
27. Burke W, Laberge AM, Press N. Debating clinical utility. Public Health Genomics 2010;13:215-223
28. Manolio TA, Chisholm RL, Ozenberger B, et al. Implementing genomic medicine in the clinic: The future is here. Genet Med 2013;15:258-267
29. Trosman JR, Van Bebber SL, Phillips KA. Coverage policy development for personalized medicine: Private payer perspectives on developing policy for the 21-gene assay. J Oncol Pract 2010;6:238-242
30. Neumann PJ, Chambers JD. Medicare's enduring struggle to define reasonable and necessary care. N Engl J Med 2012;367:1775-1777
31. Neumann PJ, Tunis SR. Medicare and medical technology-The growing demand for relevant outcomes. N Engl J Med 2010;362:377-379
32. Greenberg D, Rosen AB, Olchanski NV, Stone PW, Nadai J, Neumann PJ. Delays in publication of cost utility analyses conducted alongside clinical trials: Registry analysis. BMJ 2004;328:1536-1537
33. Veenstra DL, Piper M, Haddow JE, et al. Improving the efficiency and relevance of evidence-based recommendations in the era of whole-genome sequencing: An EGAPP methods update. Genet Med 2013;15:14-24
34. Deverka PA, Vernon J, McLeod HL. Economic opportunities and challenges for pharmacogenomics. Annu Rev Pharmacol Toxicol 2010;50: 423-437
35. Neumann PJ, Weinstein MC. Legislating against use of cost-effectiveness information. N Engl J Med 2010;363:1495-1497
36. Trosman JR, Van Bebber SL, Phillips KA. Health technology assessment and private payers' coverage of personalized medicine. J Oncol Pract 2011;7(suppl 3):18s-24s.
37. Merikangas KR, Risch N. Genomic priorities and public health. Science 2003;302:599-601
38. Bloche MG. Beyond the R word? Medicine's new frugality. N Engl J Med 2012;366:1951-1953
39. Gottlieb S, Makower J. A role for entrepreneurs: An observation on lowering healthcare costs via technology innovation. Am J Prev Med 2013;44 (1 suppl 1):S43-S47